The Three A’s of Launch Readiness – Strategizing for success

Jesper Nissen

It can take years to develop a drug – a launch can fail in a matter of weeks

Getting a drug from bench to launch takes an average of 12 years and $1.5 billion.1 Given responsible guardianship and the careful promotion to be expected at that level of investment, it should come as a surprise when any drug falls flat at launch.

But it doesn’t – drug launch failures happen more frequently than pharma companies care to admit. From 2009-2017, approximately 50% of drug launches failed to meet prelaunch sales expectations. Over 25% didn’t meet half their forecasted revenues.2 Of the 0.02% of candidate drugs (I in 5000) that successfully reach the market, only a third meet first-year financial expectation.3

And when launches fail, the rationalizations begin: Bad luck. Bad timetables. Unforeseen complications. Unforeseeable competition. The messaging underwhelmed the target audiences. The drug costs overwhelmed the messaging. The drug overpromised, the drug underperformed.

Any and all of these may be true. But, when each case is scrutinized individually, the evidence usually points to one of three problems: the pharma brand managers and their teams did not anticipate their own overconfidence or the moves of their competitors, they did not adapt their strategies to new market conditions as they arose, or they did not align their strategy and implementation plans across functions and geographies.

Anticipate, Adapt and Align – the three A’s of successful launch strategy. To understand and implement them require more than sending out an email meeting request and marking off a block of squares on a Gantt chart. It takes strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Deallus Three As of Launch Readiness White paper
DOWNLOAD WHITE PAPER

About the author

Jesper Nissen Deallus Principal, London

Jesper Nissen, PhD

Jesper is a Deallus Senior Principal who has led a wide range of projects over his 6+ years at Deallus. He offers extensive experience in competitive landscape monitoring, manufacturing and diagnostics technology assessments, and global positioning and brand planning projects. His expertise covers several therapy areas including oncology, respiratory, rheumatology and rare diseases. Additionally, Jesper is leading internal and external training activities including engagements on competitive readiness best practices within the pharmaceutical industry.

You may also be interested in…

Revolutionizing Blood Cancer Treatment: A Dive into Cutting-Edge Therapies

World Blood Cancer Day [28 May 2024] serves as a stark reminder of the significant challenges faced by the millions battling these life-threatening diseases. Here at Deallus, we have been privileged enough to partner with many leading companies in this space to support the development of lifechanging therapies across haemato-oncology.

The need for innovation in Women’s Health

Women’s Health Week (14-20 May 2024) provides an opportunity to reflect on the changing landscape for the access, treatment, and representation of women across healthcare. We’re proud that many of the clients we are partnering with are part of driving much needed change and reform within Women’s Health, lending our experience and expertise to the innovation that is required.

A message from our Chairwoman

At Deallus we are fortunate to have Ulrike Meier as our Chairwoman since 2020. Ulrike has written a brilliant blog reflecting on her time with Deallus so far and shares some insights into, even if removed from daily business, as Chairwoman, there is room to make a difference. From being authentic, focusing on the bigger picture, to providing motivation and guidance, Ulrike explores what key elements she prioritises in her role and how we can all play a part in organisation success.